Community-based harm reduction substance abuse treatment with methamphetamine-using men who have sex with men

Journal of Urban Health

Volumn 91, Issue 3, 2014, Pages 555-567

  Carrico, Adam W ^a,b   Flentje, Annesa ^a   Gruber, Valerie A ^a   Woods, William J ^b   Discepola, Michael V ^c   Dilworth, Samantha E ^b   Neilands, Torsten B ^b   Jain, Jennifer ^a   Siever, Michael D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO AIDS FOUNDATION   (United States)

Author keywords

Cognitive behavioral; Harm reduction; HIV risk; Marijuana; Methamphetamine; Treatment as prevention

Indexed keywords

METHAMPHETAMINE;

ADULT; COGNITIVE THERAPY; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; HIV INFECTIONS; HUMAN; MALE; MALE HOMOSEXUALITY; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AMPHETAMINE-RELATED DISORDERS; COGNITIVE THERAPY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; METHAMPHETAMINE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84903815780     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-014-9870-y     Document Type: Article

References (40)

1. Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010; 376(9739): 458-474.
2. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006; 20(5): 731-739. (Pubitemid 43884301)
3. Plankey MW, Ostrow DG, Stall R, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2007; 45(1): 85-92. (Pubitemid 46684447)
4. Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011; 88(21-22): 940-947.
5. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011; 56(2): 146-150.
6. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003; 188(12): 1820-1826. (Pubitemid 38064866)
7. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008; 22(11): 1355-1363.
8. Johnson MO, Carrico AW, Chesney MA, Morin SF. Internalized heterosexism among HIV-positive, gay-identified men: implications for HIV prevention and care. J Consult Clin Psychol. 2008; 76(5): 829-839.
9. Morin SF, Myers JJ, Shade SB, Koester K, Maiorana A, Rose CD. Predicting HIV transmission risk among HIV-infected patients seen in clinical settings. AIDS Behav. 2007; 11(5 Suppl): S6-S16. (Pubitemid 47319538)
10. Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. 2007; 21(2): 239-241. (Pubitemid 46036934)
11. Gorbach PM, Drumright LN, Javanbakht M, et al. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008; 47(5): 639-643. (Pubitemid 351442022)
12. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006; 101(11): 1546-1560. (Pubitemid 44527186)
13. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005; 78(2): 125-134. (Pubitemid 40544599)
14. Shoptaw S, Reback CJ, Larkins S, et al. Outcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men. J Subst Abuse Treat. 2008; 35(3): 285-293.
15. Denning P. Strategies for implementation of harm reduction in treatment settings. J Psychoactive Drugs. 2001; 33(1): 23-26. (Pubitemid 32336412)
16. Denning P. Harm reduction psychotherapy: an innovative alternative to classical addictions theory. Am Clin Lab. 2002; 21(4): 16-18.
17. Vlahov D, Des Jarlais DC, Goosby E, et al. Needle exchange programs for the prevention of human immunodeficiency virus infection: epidemiology and policy. Am J Epidemiol. 2001; 154(12 Suppl): S70-S77.
18. Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. Drug Alcohol Depend. 2007; 87(2-3): 249-257. (Pubitemid 46215934)
19. Siever MD, Discepola MV. The Stonewall Project: Available at http://www.stonewallsf.org/. Accessed 27 Feb 2013
20. McFarland W, Chen YH, Nguyen B, et al. Behavior, intention or chance? A longitudinal study of HIV seroadaptive behaviors, abstinence and condom use. AIDS Behav. 2012; 16(1): 121-131.
21. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9(3): 199-213.
22. Carrico AW, Woods WJ, Siever MD, et al. Positive affect and processes of recovery among treatment-seeking methamphetamine users. Drug Alcohol Depend. May 16 2013
23. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999; 353(9165): 1657-1661. (Pubitemid 29224522)
24. Simoes AA, Bastos FI, Moreira RI, Lynch KG, Metzger DS. A randomized trial of audio computer and in-person interview to assess HIV risk among drug and alcohol users in Rio De Janeiro. Brazil J Subst Abuse Treat Apr. 2006; 30(3): 237-243.
25. Semple SJ, Patterson TL, Grant I. Binge use of methamphetamine among HIV-positive men who have sex with men: pilot data and HIV prevention implications. AIDS Educ Prev. 2003; 15(2): 133-147. (Pubitemid 36523033)
26. Diggle PJ. Analysis of Longitudinal Data. 2nd ed. Oxford: Oxford University Press; 2002.
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New Jersey: Lawrence Erlbaum Associates; 1988.
28. Goodman L, Kruskal W. Measures of Association for Cross Classifications. New York: Springer; 1979.
29. Theil H. Statistical Decomposition Analysis. Amsterdam: North-Holland Publishing Company; 1972.
30. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics. 2002; 58: 1-12. (Pubitemid 34194482)
31. Shoptaw S, Reback CJ, Frosch DL, Rawson RA. Stimulant abuse treatment as HIV prevention. J Addict Dis. 1998; 17(4): 19-32. (Pubitemid 28556597)
32. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000; 59(1): 17-31. (Pubitemid 30116835)
33. Ostrow DG. Psychobiology of Risk Behavior. In: Gendelman H, Grant I, Everall IP, et al., eds. The neurology of AIDS. 3rd ed. New York: Oxford University Press; 2011: 1045-1051.
34. Pantalone DW, Bimbi DS, Parsons JT. Motivations for the recreational use of erectile enhancing medications in urban gay and bisexual men. Sex Transm Infect. 2008; 84(6): 458-462.
35. Ostrow DG, Plankey MW, Cox C, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009; 51(3): 349-355.
36. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6): 493-505.
37. Geng EH, Hare CB, Kahn JO, et al. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/muL in a public health setting. Clin Infect Dis. 2012; 55(12): 1690-1697.
38. Shoptaw S, Montgomery B, Williams CT, et al. Not just the needle: the state of HIV-prevention science among substance users and future directions. J Acquir Immune Defic Syndr. 2013; 63(Suppl 2): S174-178.
39. Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS. 2000; 11(9): 579-585.
40. Ball AL. HIV, injecting drug use and harm reduction: a public health response. Addiction. 2007; 102(5): 684-690. (Pubitemid 46633358)